FINGOLIMOD vs GLATIRAMER

Compare FINGOLIMOD (Fingolimod) and GLATIRAMER (Glatiramer Acetate) — clinical data, side effects, and patient experiences.

FINGOLIMOD

Fingolimod, Gilenya · Other

How it works

12.1 Mechanism of Action Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor ...

Approved for

1 INDICATIONS AND USAGE Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

OralTablet

GLATIRAMER

Glatiramer Acetate · Other

How it works

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act...

Approved for

1 INDICATIONS AND USAGE Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

SubcutaneousTablet

Quick Comparison

FINGOLIMODGLATIRAMER

Drug Class

Other

Route

Oral

Subcutaneous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

FINGOLIMOD

Fatigue

>10%

Headache

>10%

Dizziness

1-10%

Falls

1-10%

Nausea

1-10%

Drug Not Working

0.1-1%

General Unwellness

0.1-1%

GLATIRAMER

Injection Site Pain

>10%

Drug Not Working

1-10%

Injection Site Reaction

1-10%

Fatigue

1-10%

Shortness of Breath

1-10%

Falls

1-10%

Nausea

0.1-1%

Dizziness

0.1-1%

FDA Warnings

FINGOLIMOD

5 WARNINGS AND PRECAUTIONS Infections: Fingolimod may increase the risk
Diabetes mellitus and uveitis increase the risk
7 ) Fetal Risk: May cause fetal harm
Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 2 months after stopping fingolimod

GLATIRAMER

5 WARNINGS AND PRECAUTIONS • Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting ( 5
6 ) • Glatiramer Acetate Products and Administration Errors: Using an optional autoinjector that is not compatible for use with Mylan’s glatiramer acetate injection may increase the risk for medication errors, such as dose omission or administration of a partial dose
1 Anaphylactic Reactions Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection [see Adverse Reactions (6
Glatiramer acetate injection is contraindicated in patients with a history of hypersensitivity reactions to glatiramer acetate injection, including anaphylaxis [see Contraindications (4) ]

Clinical Trial Data

No head-to-head clinical studies found for FINGOLIMOD vs GLATIRAMER.

FINGOLIMOD vs GLATIRAMER: What You Should Know

Key Differences

Both FINGOLIMOD and GLATIRAMER belong to the Other class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. FINGOLIMOD is administered via Oral, whereas GLATIRAMER uses Subcutaneous. Route of administration can affect onset of action and patient adherence.

Shared Indications

Both medications are approved for to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, to include clinically isolated syndrome. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.

Safety Considerations

FINGOLIMOD carries 4 FDA warnings. GLATIRAMER carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

DIMETHYL FUMARATE vs FINGOLIMOD→DIMETHYL FUMARATE vs GLATIRAMER→FINGOLIMOD vs TERIFLUNOMIDE→FINGOLIMOD vs SIPONIMOD→FINGOLIMOD vs PONESIMOD→CLADRIBINE vs FINGOLIMOD→

Loading comparison data...

FINGOLIMOD vs GLATIRAMER

Compare FINGOLIMOD (Fingolimod) and GLATIRAMER (Glatiramer Acetate) — clinical data, side effects, and patient experiences.

FINGOLIMOD

Fingolimod, Gilenya · Other

How it works

12.1 Mechanism of Action Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor ...

Approved for

1 INDICATIONS AND USAGE Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

OralTablet

GLATIRAMER

Glatiramer Acetate · Other

How it works

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatiramer acetate is thought to act...

Approved for

1 INDICATIONS AND USAGE Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

SubcutaneousTablet

Quick Comparison

FINGOLIMODGLATIRAMER

Drug Class

Other

Route

Oral

Subcutaneous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

FINGOLIMOD

Fatigue

>10%

Headache

>10%

Dizziness

1-10%

Falls

1-10%

Nausea

1-10%

Drug Not Working

0.1-1%

General Unwellness

0.1-1%

GLATIRAMER

Injection Site Pain

>10%

Drug Not Working

1-10%

Injection Site Reaction

1-10%

Fatigue

1-10%

Shortness of Breath

1-10%

Falls

1-10%

Nausea

0.1-1%

Dizziness

0.1-1%

FDA Warnings

FINGOLIMOD

5 WARNINGS AND PRECAUTIONS Infections: Fingolimod may increase the risk
Diabetes mellitus and uveitis increase the risk
7 ) Fetal Risk: May cause fetal harm
Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 2 months after stopping fingolimod

GLATIRAMER

5 WARNINGS AND PRECAUTIONS • Immediate Post-Injection Reaction (flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and/or urticaria), may occur within seconds to minutes after injection and are generally transient and self-limiting ( 5
6 ) • Glatiramer Acetate Products and Administration Errors: Using an optional autoinjector that is not compatible for use with Mylan’s glatiramer acetate injection may increase the risk for medication errors, such as dose omission or administration of a partial dose
1 Anaphylactic Reactions Life-threatening and fatal anaphylaxis has been reported with glatiramer acetate injection [see Adverse Reactions (6
Glatiramer acetate injection is contraindicated in patients with a history of hypersensitivity reactions to glatiramer acetate injection, including anaphylaxis [see Contraindications (4) ]

Clinical Trial Data

No head-to-head clinical studies found for FINGOLIMOD vs GLATIRAMER.

FINGOLIMOD vs GLATIRAMER: What You Should Know

Key Differences

Shared Indications

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.